Business
CollPlant Enriches Portfolio of rhCollagen-Based Bioinks with Launch of Collink.3DTM 50L in Powder Form
Company's first bioink available in powder form provides enhanced operational flexibility to support a wide range of 3D bioprinting applicationsCollink.3D™
About this update from Collplant Biotechnologies Ltd.
[{"type":"text","content":"Company's first bioink available in powder form provides enhanced operational flexibility to support a wide range of 3D bioprinting applicationsCollink.3D™ 50L strengthens CollPlant's platform of bioink solutions to biopharma and academic customers seeking animal-free alternatives with improved bio-functionality, safety and reproducibility REHOVOT, Israel, Jan. 3, 2023 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing, today announced the launch of Collink.3DTM 50L, a recombinant human collagen (rhCollagen)-based bioink in a powder form for use in a wide range of 3D bioprinting applications, including drug discovery, drug screening, tissue testing as well as the development of transplantable tissues and organs.\n\n \n \n \n \n \n \n\n \nCollink.3DTM 50L, the result of a comprehensive development effort, is a tunable bioink that can be easily reconstituted to form solutions with application-specific concentrations, formulated with other components and crosslinked to form hydrogels that meet the demand for specific geometric, physical and biological properties of different 3D constructs. Collink.3D™ 50L adds to CollPlant's growing portfolio of commercial bioinks launched over the last year, Collink.3DTM 50 and Collink.3DTM 90.\n\"We continue to innovate and support the biopharma and academia with their 3D bioprinting applications by offering a commercial bioink in powder form that improves operational flexibility, including more convenient shipment, handling and storage of the product,\" said CollPlant CEO, Yehiel Tal. \"Much like our other bioinks, Collink.3DTM 50L provides a state-of-the-art animal-free alternative to existing commercial bioinks, enabling high-resolution, scalable and reproduceable bioprinting of scaffolds that accurately mimic the physical properties of human tissues and organs. Our bioink platform is intended to enable our customers to streamline the process of new product development while also accelerating timelines and reducing overall costs,\" added Tal. \nBiofabricated constructs composed of Collink.3DTM offer superior biological performance, consistency and safety. The Collink.3D™ platform is compatible with major 3D bioprinting technologies and cell ...